The survival advantage shown in patients with prostate cancer taking DPP4 inhibitors only (HR 0.77; 95% CI: 0.64–0.93; P = 0.005) shows the benefit independent of metformin. This evidence concerns the gene DPP4 and prostate carcinoma.